Topical PDE4 Inhibitor for Plaque Psoriasis Passes Muster With FDA
Roflumilast cream first topical agent that specifically improved intertriginous psoriasis
Stay updated with breaking news from Mark Lebwohl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roflumilast cream first topical agent that specifically improved intertriginous psoriasis
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica -Study... | June 30, 2022
Vtama (tapinarof) is a new treatment for psoriasis that, unlike topical steroids, that can be used anywhere on the body and without time restrictions.
- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician
Plaque psoriasis drug Vtama is now approved by the FDA, making it the first novel topical treatment for the chronic autoimmune disorder in a generation. Roivant Sciences subsidiary Dermavant Sciences acquired the drug from GlaxoSmithKline in 2018.